Biohaven Ltd. (BHVN)
11.39
+0.32
(+2.89%)
USD |
NYSE |
Jun 11, 15:12
Biohaven Enterprise Value : 1.603B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 1.603B |
| June 09, 2026 | 1.606B |
| June 08, 2026 | 1.610B |
| June 05, 2026 | 1.562B |
| June 04, 2026 | 1.652B |
| June 03, 2026 | 1.564B |
| June 02, 2026 | 1.461B |
| June 01, 2026 | 1.657B |
| May 29, 2026 | 1.594B |
| May 28, 2026 | 1.478B |
| May 27, 2026 | 1.636B |
| May 26, 2026 | 1.453B |
| May 22, 2026 | 1.359B |
| May 21, 2026 | 1.364B |
| May 20, 2026 | 1.269B |
| May 19, 2026 | 1.200B |
| May 18, 2026 | 1.215B |
| May 15, 2026 | 1.256B |
| May 14, 2026 | 1.295B |
| May 13, 2026 | 1.296B |
| May 12, 2026 | 1.322B |
| May 11, 2026 | 1.304B |
| May 08, 2026 | 1.421B |
| May 07, 2026 | 1.403B |
| May 06, 2026 | 1.448B |
| Date | Value |
|---|---|
| May 05, 2026 | 1.399B |
| May 04, 2026 | 1.463B |
| May 01, 2026 | 1.387B |
| April 30, 2026 | 1.381B |
| April 29, 2026 | 1.321B |
| April 28, 2026 | 1.383B |
| April 27, 2026 | 1.380B |
| April 24, 2026 | 1.424B |
| April 23, 2026 | 1.520B |
| April 22, 2026 | 1.544B |
| April 21, 2026 | 1.470B |
| April 20, 2026 | 1.565B |
| April 17, 2026 | 1.589B |
| April 16, 2026 | 1.443B |
| April 15, 2026 | 1.497B |
| April 14, 2026 | 1.508B |
| April 13, 2026 | 1.460B |
| April 10, 2026 | 1.317B |
| April 09, 2026 | 1.350B |
| April 08, 2026 | 1.348B |
| April 07, 2026 | 1.330B |
| April 06, 2026 | 1.314B |
| April 02, 2026 | 1.412B |
| April 01, 2026 | 1.385B |
| March 31, 2026 | 1.210B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 1.979M |
| Brainstorm Cell Therapeutics, Inc. | 10.63M |
| Summit Therapeutics, Inc. | 9.548B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 75.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -130.53M |
| Total Expenses (Quarterly) | 130.53M |
| EPS Diluted (Quarterly) | -0.8843 |
| Earnings Yield | -49.78% |
| Normalized Earnings Yield | -49.91 |